مقایسهٔ روش‌ها

	ارزیابی کیفیت زندگی بیماران مبتلا به یبوست	GERD Health-Related Quality of Life Scale	معیارهای تشخیصی رم IV برای سندرم روده تحریک‌پذیر
حوزه	گوارش	گوارش	گوارش
خانواده	Process / pipeline	Process / pipeline	Process / pipeline
سال پیدایش	2005	1996	2016
پدیدآور	Marquis, P., De La Loge, C., Dubois, D., et al.	Velanovich, V., Zhang, Y., Hollis, J. B., et al.	Rome Foundation (multinational expert consensus)
نوع	Self-report	Self-report	Diagnostic Criteria
منبع بنیادین	Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005). Development and validation of the Patient Assessment of Constipation-Quality of Life questionnaire. Scandinavian Journal of Gastroenterology, 40(5), 540–551.	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.
نام‌های دیگر	PAC-QoL, PAC-Q	GERD-HRQL, GERD-HRQoL	Rome IV IBS, Rome Criteria
مرتبط	4	4	4
خلاصه	The Patient Assessment of Constipation Quality of Life (PAC-QoL) is a validated, patient-reported outcome measure designed to assess the impact of functional constipation on physical, psychological, and social well-being. Developed by Marquis and colleagues in 2005, the PAC-QoL comprises 28 items organized into four domains: Physical Discomfort, Psychosocial Discomfort, Worries and Concerns, and Satisfaction. The PAC-QoL is responsive to treatment and widely used in constipation clinical trials and practice.	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.